Posted on

Long-Term Phase 3 Study Shows Esketamine Nasal Spray Plus an Oral Antidepressant Delayed Time to Relapse in Patients with Treatment-Resistant Depression

Long-Term Phase 3 Study Shows Esketamine Nasal Spray Plus an Oral Antidepressant Delayed Time to Relapse in Patients with Treatment-Resistant Depression
TITUSVILLE, N.J., May 31, 2018 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from two long-term Phase 3 clinical studies of the investigational compound esketamine nasal spray in patients with ... .... ( read more )
Orginally Published At: Drugs – Clinical Trials